Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.62 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26208037 | 0.92 | HINT1 (0.58) | HINT1GSK3ARPS6KA3MAPK14ADORA2A | |
| SCHEMBL1533274 | 0.90 | HINT1 (0.73) | HINT1GSK3ARPS6KA3MAPK14ADORA2A | |
| SCHEMBL26622675 | 0.90 | NT5E (0.61) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL26212718 | 0.89 | HINT1 (0.59) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL26808396 | 0.87 | HINT1 (0.60) | HINT1GSK3ARPS6KA3MAPK14ADORA2A | |
| SCHEMBL26808259 | 0.87 | HINT1 (0.60) | HINT1GSK3ARPS6KA3MAPK14ADORA2A | |
| SCHEMBL26622682 | 0.87 | TGM2 (0.62) | HINT1NT5ETGM2 | |
| SCHEMBL26622652 | 0.87 | HINT1 (0.63) | HINT1GSK3ARPS6KA3MAPK14ADORA2A | |
| SCHEMBL31516979 | 0.86 | HINT1 (0.62) | HINT1GSK3ARPS6KA3MAPK14ADORA2A | |
| SCHEMBL31516974 | 0.86 | HINT1 (0.62) | HINT1GSK3ARPS6KA3MAPK14ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | HINT1 706/4885GSK3A 4107/4885RPS6KA3 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.